Antibody-mediated interferences affecting cardiac troponin assays: recommendations from the IFCC Committee on Clinical Applications of Cardiac Biomarkers

Ola Hammarsten, Janet V Warner, Leo Lam, Peter Kavsak, Bertil Lindahl, Kristin M Aakre, Paul Collinson, Allan S Jaffe, Amy K Saenger, Richard Body, Nicholas L Mills, Torbjørn Omland, Jordi Ordonez-Llanos, Fred S Apple

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

The International Federation of Clinical Chemistry Committee on Clinical Applications of Cardiac Biomarkers (IFCC C-CB) provides educational documents to facilitate the interpretation and use of cardiac biomarkers in clinical laboratories and practice. Our aim is to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay. Measurements of cardiac troponin (cTn) have a prominent place in the clinical work-up of patients with suspected acute coronary syndrome. It is therefore important that clinical laboratories know how to recognize and assess analytical issues. Two emerging analytical issues resulting in falsely high cTn concentrations, often several fold higher than the upper reference limit (URL), are antibody-mediated assay interference due to long-lived cTn-antibody complexes, called macrotroponin, and crosslinking antibodies that are frequently referred to as heterophilic antibodies. We provide an overview of antibody-mediated cTn assay interference and provide recommendations on how to confirm the interference and interpret the results.

Original languageEnglish
Number of pages9
JournalClinical Chemistry and Laboratory Medicine
Early online date24 Mar 2023
DOIs
Publication statusE-pub ahead of print - 24 Mar 2023

Fingerprint

Dive into the research topics of 'Antibody-mediated interferences affecting cardiac troponin assays: recommendations from the IFCC Committee on Clinical Applications of Cardiac Biomarkers'. Together they form a unique fingerprint.

Cite this